Valsartan Lawsuit Lawyer – Settlement & Recall - Liver Injury & Cancer

The Valsartan lawsuits claim that numerous batches of Valsartan have been found to be contaminated with the cancer-causing substances N-nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), and/or N-Methylnitrosobutyric acid (NMBA).

Our law firm is accepting clients who took valsartan and have been diagnosed with liver damage, tumors, or cancer.

 

What Do We Know About the Valsartan Lawsuits

Valsartan Litigation

Several drug companies have voluntarily recalled their blood pressure and heart medication that contains valsartan after it was discovered that the medication might have become contaminated in the Chinese and India manufacturing plants it was being produced.

The companies involved include Actavis; A-S Medication Solutions; AvKARE; Bryant Rank Prepack; Camber Pharmaceuticals; Hetero Labs, Inc.; HJ Harkins Company; Major Pharmaceuticals; Mylan Pharmaceuticals; Northwind Pharmaceuticals; NuCare Pharmaceuticals; Preferred Pharmaceuticals; Prinston Pharmaceutical; RemedyRepack Inc.; Solco Healthcare; Teva Pharmaceuticals; and Torrent Pharmaceuticals Limited.

A complete list of the recalled products can be found at angiotensin II receptor blockers recall list.

The Key Legal Issue

Valsartan (a generic version of Diovan) might have become contaminated with the chemicals N-nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), and/or N-Methylnitrosobutyric acid (NMBA) if produced by Zhejiang Huahai Pharmaceuticals or Hetero Labs Limited. Potential injuries include liver damage, tumors, and cancer.

 

Valsartan Injuries & Side Effects

Valsartan is an angiotensin II receptor blocker (ARB) used to treat hypertension (high blood pressure), recent heart attacks, and heart failure.

Certain batches of valsartan produced by the Chinese company Zhejiang Huahai Pharmaceuticals and the India company Hetero Labs Limited have been contaminated with N-nitrosodimethylamine (NDMA). This chemical is a known carcinogen.

Short-term exposure to NDMA can cause liver damage (such as liver fibrosis and scarring). Long-term exposure can increase the risk of liver, kidney, and lung tumors.

According to the Environmental Protection Agency (EPA), NDMA is not currently produced in pure form or commercially used in the United States, except for research purposes.

It was formerly used in production of liquid rocket fuel, antioxidants, additives for lubricants, and softeners for copolymers.

Symptoms of NDMA Overexposure

Symptoms of NDMA overexposure include headaches; fever; nausea; jaundice; vomiting; abdominal cramps; enlarged liver; reduced function of the liver, kidneys and lungs; and dizziness.
 

Compensation in a Valsartan Lawsuit

If you were taking any of the valsartan medications contaminated with N-nitrosodimethylamine, and have experienced liver damage, tumor, or cancer, we will be seeking the following damages for you:

  1. Past and future medical expenses to treat your injuries.
  2. Past and future pain and suffering that results from your injuries, both from a physical and mental standpoint.
  3. Wage loss, if any.
  4. Other economic losses experienced because of your injuries.
  5. Punitive damages, if appropriate.

 
 
Why Choose Our Law Firm

Our law firm started handling personal injury cases in 1955. Today, we are recognized as a national leader in lawsuits involving drug injuries. We have received over 150 jury verdicts for $1 million or more, and have won jury verdicts and settlements in excess of $4 billion.

We are the founder of Mass Torts Made Perfect. This is a national conference attended by 1,500 lawyers each year where we teach how to successfully handle lawsuits against drug manufacturers. For more information, please visit our About Us section.

in Business 63 years * $4 Billion in Verdicts & Settlements * Best Law Firms: U.S. News & World Reports * Trial Lawyers Hall of Fame * SuperLawyers
 
Our Fees & Costs

Our lawyers provide free confidential case evaluations, and we never charge any fees or costs unless you first recover.

The contingency fee we charge ranges from 20% to 40%. The amount we charge is based on how much we recover for you. To review a summary of our fees and costs, click Fees & Costs.

 
Free Case Evaluation

To contact us for a free case evaluation, you can call us at (800) 277-1193. You also can request an evaluation by clicking Free & Confidential Valsartan Evaluation Form. This form will be immediately reviewed by one of our attorneys handling the Valsartan litigation.

Read More

Will My Valsartan Case be Handled as a Class Action?

A class action is a lawsuit where a few individuals represent the interest of many individuals. The court rulings are binding on all persons who are a part of the class action. All class members are required to accept the settlement, even if an individual is going to receive little or no compensation.

Our Valsartan attorneys will not be pursuing class actions for our clients. Instead, we represent each client on his/her specific facts, and we evaluate each client's damages on his/her specific facts. Each of our clients has the option of settling or not settling his/her case.

For a detailed discussion on class actions, mass torts, and multidistrict litigation, please visit our Class Action Mass Torts Page.

 

Valsartan Lawsuit Settlement Amounts

 Valsartan compensation

As of this time, there have been no large group settlements involving Valsartan. Litigation likes this takes many years to resolve, with teams of lawyers spending millions of dollars trying to determine exactly what occurred, and how it could have been prevented.

Generally, large groups of settlements do not occur until such time as a few cases are tried before a jury, and the manufacturer is able to more thoroughly understand its financial risk. The first step in this process is usually having large groups of cases combined in federal court for discovery purposes. This process is known as Multi-District Litigation (known as an MDL).

In February 2019, an MDL was established for Valsartan in federal court in New Jersey. Our law firm is serving as co-lead counsel for the MDL, which means that we are helping to lead up the nationwide litigation and hopefully a global settlement.

 

Valsartan Warnings & Recalls

In May 2018, the European Medicines Agency (EMA) began reviewing medicines containing valsartan that was supplied by Zhejiang Huahai Pharmaceuticals. The review started after the company detected NDMA in the valsartan it was supplying to manufacturers in the European Union.

In July 2018, the FDA announced that three companies were voluntarily recalling their medications containing valsartan that was supplied by the Chinese company Zhejiang Huahai Pharmaceuticals. The recall occurred after the company determined the presence of NDMA in the valsartan. The FDA also provided guidance to manufacturers regarding how to properly test their valsartan for possible NDMA contamination.

It’s believed that the Chinese company’s production of valsartan could have become contaminated with NDMA starting in 2012 after the company changed its manufacturing process.

In August 2018 , the FDA announced that certain batches of valsartan produced by India company Hetero Labs Limited and sold under the label Camber Pharmaceuticals also will be recalled because of the presence of NDMA.

In August 2018, Torrent Pharmaceuticals announced the voluntary recall of 14 lots of Valsartan/Amlodipine/HCTZ tablets due to the presence of NDMA.

In November 2018, Teva Pharmaceuticals voluntarily recalled all lots of amlodipine/valsartan combination tablets and amlodipine/valsartan/hydrochlorothiazide combination tablets after NDEA was detected in an active pharmaceutical ingredient manufactured by Mylan India.

Since November 2018, numerous lots of Valsartan/Amlodipine/HCTZ tablets have been recalled for various forms of contamination with NDMA, NDEA, and/or NMBA.

 

Attorneys Mike Papantonio and Daniel Nigh Discuss the Valsartan Lawsuits

 
Watch More Videos
 

What is the Purpose of Valsartan

Valsartan Banner

Valsartan is an angiotensin II receptor blocker (ARB) used to treat hypertension (high blood pressure), recent heart attacks, and heart failure. The medication is usually available in tablets containing valsartan 40 mg, 80 mg, 160 mg, or 320 mg.

The drug was created by pharmaceutical company Novartis and approved by the FDA in 1996. Today, the drug is produced by numerous companies.

Valsartan should be discontinued upon pregnancy as it can result in fetal toxicity, and cause injury and death to the developing fetus.

Additionally, Valsartan should be used with caution when a patient shows signs of hereditary angioedema, volume depletion, severe congestive heart failure (CHF), hyperkalemia, hepatic or renal impairment, aortic or mitral valve stenosis.

 

Valsartan Lawsuit News

Popular Heart Drugs Tainted With Carcinogens Face a Wave of Lawsuits

“My best estimate sitting here today is I expect that we will have approximately 2,000 personal-injury cases on file in the next two years,” Daniel Nigh, who has filed 12 such lawsuits so far, told judges at a conference in the U.S. District Court in New Jersey last month, according to a transcript. To read more, click Bloomberg Drug Lawsuits

Tainted drugs: Ex-FDA inspector warns of dangers in U.S. meds made in China, India

The valsartan recall came as little surprise to Massoud Motamed, a former inspector with the U.S. Food and Drug Administration (FDA). More than a year before the notices went out, Motamed had tried to sound the alarm on what he flagged as potential systemic problems at two facilities in China and India that produce the active ingredients in generic valsartan and other blood pressure medications. To read more, click NBC Tainted Drugs

Recall of heart drug valsartan continues to expand

The US Food and Drug Administration has again expanded the list of recalled medications that contain valsartan, used as a component in a set of drugs to treat heart failure and blood pressure. To read more, click CNN Continued Recall

Valsartan recall: 4 things patients should know

The FDA action came after 22 other countries issued recalls involving 2,300 valsartan batches sent to Germany, Norway, Finland, Sweden, Hungary, the Netherlands, Austria, Ireland, Bulgaria, Italy, Spain, Portugal, Belgium, France, Poland, Croatia, Lithuania, Greece, Canada, Bosnia and Herzegovina, Bahrain and Malta. To read more, click CNN Recall Knowledge

Blood Pressure Medicine Is Recalled

Three companies that sell the generic drug, valsartan, in the United States agreed to recall it after the F.D.A. said it might be tainted by N-nitrosodimethylamine (NDMA), considered a probable human carcinogen. To read more, click New York Times

 

FDA and Scientific Studies Regarding Valsartan

FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)

This website is a comprehensive list of the various announcements by the FDA regarding the Valsartan contamination issues. To read more, click FDA Updated Valsartan Recall

FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity

The U.S. Food and Drug Administration is alerting health care professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure. This recall is due to an impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled products. However, not all products containing valsartan are being recalled. To read more, click FDA Safety Announcement

FDA Finds NDEA in Torrent Pharmaceuticals Valsartan Products

The FDA’s latest testing of products shows an additional unexpected impurity in three lots of Torrent Pharmaceuticals’ recalled valsartan drug products. This second impurity, N-Nitrosodiethylamine (NDEA) is a known animal and suspected human carcinogen. To read more, click FDA Valsartan Update

Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer

The results of this study do not imply a markedly increased short term overall risk of cancer in users of valsartan contaminated with NDMA. However, uncertainty persists about single cancer outcomes, and studies with longer follow-up are needed to assess long term cancer risk. To read more, click British Medical Journal

 
Awards
AWARDS
  • Best Law Firms: U.S. News & World Report
  • Best Lawyers in America
  • National Trial Lawyers Hall of Fame
  • Public Justice Trial Team of the Year
  • Martindale-Hubbell Preeminent Woman Attorney
  • National Law Journal Elite Trial Lawyers
  • SuperLawyers
 
Awards
AWARDS
  • Best Law Firms: U.S. News & World Report
  • Best Lawyers in America
  • National Trial Lawyers Hall of Fame
  • Public Justice Trial Team of the Year
  • Martindale-Hubbell Preeminent Woman Attorney
  • National Law Journal Elite Trial Lawyers
  • SuperLawyers
 
Jury Verdicts
JURY VERDICTS
  • $1 Billion in Defective Product Case
  • $480 Million in Airplane Crash
  • $380 Million in Environmental Pollution Case
  • $150 Million in Defective Drug Case
  • $42 Million in Fraud Case
  • $31 Million in Medical Malpractice Case
  • $25 Million in Motor Vehicle Accident
  • $18 Million in Train Derailment
Jury Verdicts
JURY VERDICTS
  • $1 Billion in Defective Product Case
  • $480 Million in Airplane Crash
  • $380 Million in Environmental Pollution Case
  • $150 Million in Defective Drug Case
  • $42 Million in Fraud Case
  • $31 Million in Medical Malpractice Case
  • $25 Million in Motor Vehicle Accident
  • $18 Million in Train Derailment
Testimonials
CLIENT STATEMENTS

Here are some of the notes clients have sent us:

You saved my life.
I want to express my deepest appreciation.
You mean so much to our family.
I am so appreciative.

To read our client reviews, visit our Testimonial page.

 
Testimonials
CLIENT STATEMENTS

Here are some of the notes clients have sent us:

You saved my life.
I want to express my deepest appreciation.
You mean so much to our family.
I am so appreciative.

To read our client reviews, visit our Testimonial page.